LFG Wealth Partners LLC Purchases Shares of 29,136 Novo Nordisk A/S $NVO

LFG Wealth Partners LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, HoldingsChannel reports. The fund acquired 29,136 shares of the company’s stock, valued at approximately $1,071,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Revolve Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC lifted its position in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares in the last quarter. Invesco Ltd. boosted its holdings in Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $314,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Up 0.3%

NYSE NVO opened at $47.20 on Monday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company has a market capitalization of $210.74 billion, a price-to-earnings ratio of 11.08, a price-to-earnings-growth ratio of 4.30 and a beta of 0.77. The company’s fifty day moving average price is $46.92 and its two-hundred day moving average price is $45.40.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.